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Abstract: Neural stem cells (NSCs) are self-renewing multipotent cells that generate the main phenotypes of the nervous 
system, neurons, astrocytes and oligodendrocytes. As such they hold the promise to treat a broad range of neurological 
diseases and injuries. Neural progenitor and stem cells have been isolated and characterized in vitro, from adult, fetal and 
post-mortem tissues, providing sources of material for cellular therapy. However, NSCs are still elusive cells and remain to 
be unequivocally identiﬁ  ed and characterized, limiting their potential use for therapy. Neural progenitor and stem cells, 
isolated and cultured in vitro, can be genetically modiﬁ  ed and when transplanted migrate to tumor sites in the brain. These 
intrinsic properties of neural progenitor and stem cells provide tremendous potential to bolster the translation of NSC research 
to therapy. It is proposed to combine gene therapy and cellular therapy to treat brain cancers. Hence, neural progenitor and 
stem cells provide new opportunities for the treatment of brain cancers.
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Introduction
Cancers result from genetic and epigenetic changes in normal growth-controlled cells; the cells become 
unable to terminally differentiate, to control their ability to proliferate, and acquire the ability to invade 
other tissues and spread through the body or metastasize (Cahill et al. 1999). In the central nervous system 
(CNS), tumors that originate in the brain or spinal cord are called primary tumors. Primary brain tumors 
are named according to the type of cells or the part of the brain in which they begin. Most primary tumors 
originate from out-of-control growth among cells that surround and support neurons. The most common 
primary brain tumors are gliomas. They begin in glial cells. There are many types of gliomas, like astro-
cytoma in which the tumor arises from a population of glial cells called astrocytes, ependymoma in which 
the tumor arises from cells that line the ventricles or the central canal of the spinal cord, oligodendroglioma 
in which the tumor arises from oligodendrocytes. Some types of brain tumors do not begin in glial cells, 
like medulloblastoma that usually arises in the cerebellum, meningioma that arises in the meninges. When 
cancer cells spread to the brain from another organ, like the lung or breast, the tumors in the brain are 
called secondary tumors or metastatic tumors. Secondary tumors in the brain are more common than 
primary brain tumors. Brain tumors are rated by grade, from low grade (grade I) to high grade (grade IV), 
corresponding to the way the cells look under a microscope. Cells from high-grade tumors look more 
abnormal, and generally grow faster than cells from low-grade tumors. The CNS is housed within rigid, 
bony quarters (i.e. the skull and spinal column), so any abnormal growth, whether benign or malignant, 
can place pressure on sensitive tissues, impair function and be life threatening. Surgery, radiation and 
chemotherapy are the three most commonly used treatments for brain tumors (Kaal et al. 2005).
Neural Stem Cells and Cellular Therapy
Stem cells are the building blocks of the body (Potten and Loefﬂ  er, 1990). Pluripotent stem cells can 
generate cells participating to the three germ layers of the individuals, the ectoderm, mesoderm and 
endoderm, and the germ cells. Multipotent stem cells generate lineage speciﬁ  c cell types restricted to 
the tissues from which they are derived. Pluripotent stem cells are present in embryonic tissues and 
multipotent stem cells are present in fetal and adult tissues. During development, multipotent stem cells 
contribute to the formation of the tissues and in the adult they contribute to homeostasis of the tissues and 452
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regeneration after injury. In the mammalian 
nervous system, during development, newborn 
neuronal cells originate from NSCs in the 
ventricular zone (Angevine, 1965). In the adult 
brain, contrary to a long-held dogma, neurogenesis 
occurs in the adult brain and NSCs reside in the 
adult CNS (Gross, 2000), in various species includ-
ing humans (Taupin and Gage, 2002).
Neural progenitor and stem cells have been 
isolated and characterized in vitro from various 
regions of the fetal, adult and post-mortem brain 
tissues, from various species including humans 
(Ryder et al. 1990; Reynolds and Weiss, 2002; 
Gage et al. 1995; Roy et al. 2000; Palmer et al. 
2001). Neural progenitor cells are multipotent cells 
with limited proliferative capacity. Because of their 
potential to generate the main phenotypes of the 
nervous system, NSCs have the potential to treat 
a broad range of diseases and injuries of the ner-
vous system, like neurodegenerative diseases, 
strokes and spinal cord injuries (Taupin et al. 
2006).
Potential of Neural Progenitor 
and Stem Cells for Brain Tumor 
Therapy
Neural progenitor and stem cells have intrinsic 
properties that make them particularly interesting 
and valuable for therapy (Dwain et al. 2006). Neu-
ral progenitor and stem cells isolated from fetal 
tissues and expanded in vitro migrate to degener-
ated, injured and tumor sites in the nervous system, 
when transplanted in the CNS, or when adminis-
tered by systemic injection, in blood vessels or in 
the cerebrospinal ﬂ  uid, by injecting cells into the 
4th ventricle in the rat (Aboody et al. 2000; Brown 
et al. 2003; Macklis, 1993; Wu et al. 2002; Fujiwara 
et al. 2004; Jeon et al. 2008). A recent study has 
reported that systemic injection of neural pro-
genitors and stem cells may provide signiﬁ  cant 
clinical beneﬁ  t in an animal model of multiple 
sclerosis (Pluchino et al. 2003). These properties 
considerably broadened the spectrum of diseases 
and injuries that can be treated using neural pro-
genitor and stem cells, like Alzheimer’s disease, 
Huntington’s disease and multiple sclerosis—
where the degeneration is widespread and for 
which “classic” cell transplantation may not be 
suitable.
Such properties of NSCs can then be used not 
only for the treatment of neurodegenerative 
diseases where the degeneration is widespread, but 
also as mode of delivering NSCs for cellular 
therapy, avoiding the practice of surgical proce-
dures, and their associated risks and secondary 
effects. Systemic injection and injection through 
the cerebrospinal ﬂ  uid are regarded as a promising 
ways to administer NSCs for cellular therapy, 
particularly for the treatment of spinal cord injury, 
with minimum damages to the host tissue and 
limiting the surgical procedure (Bai et al. 2003; 
Bakshi et al. 2004).
Neural progenitor and stem cells isolated from 
fetal and adult tissues and expanded in vitro can 
be genetically engineered (Gage et al. 1995; Liu 
et al. 1999). Niemann-Pick’s disease is a lysosomal 
storage disorder in which deﬁ  ciency of acid sphin-
gomyelinase leads to the intracellular accumulation 
of sphingomyelin and cholesterol in lysosomes 
(Kolodny, 2000). Genetically engineered neural 
progenitor and stem cells expressing acid sphin-
gomyelinase have been reported to reverse lyso-
somal storage pathology in animal models of 
Niemann-Pick’s disease (Shihabuddin et al. 2004), 
conﬁ  rming the potential of NSCs to serve as a 
gene transfer vehicle for the treatment of CNS 
pathology, particularly for lysosomal storage 
diseases. Hence, genetically engineered neural 
progenitor and stem cells extend their potential use 
for the treatment of neurological diseases caused 
by a genetic deﬁ  ciency, but also to promote neu-
ronal survival in neurodegenerative diseases (Chen 
et al. 2007).
The properties of neural progenitor and stem 
cells to be genetically engineered and to migrate 
to tumor sites have been proposed for the treatment 
of brain tumors. It is proposed to genetically engi-
neer neural progenitor and stem cells with “suicide 
genes”, like genes coding for cytolytic activities 
or anti-tumor cytokines. Transplanted or peripher-
ally administered, such genetically engineer neural 
progenitor and stem cells would then migrate to 
tumor sites where they would attack and destroy 
tumor cells (Yip et al. 2003; Shah et al. 2005).
Perspectives for the Treatment 
of Brain Tumors
The cause of most primary tumors remains 
unknown, though in some cases, speciﬁ  c genetic 
diseases (e.g. neuroﬁ  bromatosis), exposure to radi-
ation or cancer-causing chemicals are suspected. 
Because of their properties to live for long period 453
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of time and divide over time (self-renewal), 
mutations and epigenetic changes would accumu-
late in stem cells, leading to aberrant growth and 
tumor formation (Kondo, 1983).
It is proposed that the carcinogenic process may 
start in a stem cell (Trosko and Chang, 1989; Lapidot 
et al. 1994). According to this theory, tumors would 
originate from the transformation of normal stem 
cells to cancer cells, i.e. cancer stem cells (CSCs) 
(Reya et al. 2001). Recently, CSCs have been 
isolated and characterized prospectively from brain 
tumors (Singh et al. 2004a). The identiﬁ  cation of 
CSCs from brain tumors or brain tumor stem cells 
(BTSCs) has been made by applying the principles 
of stem cell biology to brain tumor cell populations 
(Hemmati et al. 2003; Pardal et al. 2003; Singh et al. 
2003; Vescovi et al. 2006; Kong et al. 2008). Though 
there are accumulated evidences for a stem origin 
for cancers, the hypothesis about NSCs or BTSCs 
as a cell population highly susceptible for neoplastic 
transformation, and responsible for tumor recurrence 
after local treatments in the CNS, is still highly 
controversial and remains to be further conﬁ  rmed 
(Singh et al. 2004b; Uchida et al. 2004; Jackson and 
Alvarez-Buylla, 2008). The stem cell theory of 
carcinogenesis predicts that cancer cells and normal 
stem cells may share common mechanisms and 
pathways (Jandial et al. 2008). Therefore, the 
identification of BTSCs may also lead to a 
better understanding of the mechanisms leading 
to carcinogenesis and therapy (Al-Hajj et al. 2004; 
Ruiz-Lozano and Rajan, 2007). However, 
though the evidences are compelling, cancers 
and brain cancers may not be a disease originating 
purely in stem cells. The origin of brain tumors 
remains therefore to be further investigated and 
conﬁ  rmed.
Conclusion
The conﬁ  rmation that adult neurogenesis occurs 
in the adult brain and NSCs reside in the adult 
CNS suggests that the adult brain may be ame-
nable to repair. Despite intense work, NSCs are 
still elusive cells and remain to be fully identiﬁ  ed 
and characterized in vitro and in vivo. Further 
identiﬁ  cation and characterization of NSCs are 
prerequisite to bring NSC research to therapy. 
Properties of NSCs to migrate to tumors and to be 
genetically engineered provide a promising oppor-
tunity to treat brain tumors. Neural progenitor and 
stem cells have tremendous consequences not only 
for our understanding of brain development and 
cellular therapy, but also for the origin of brain 
tumors. The isolation and characterization of 
BTSCs suggest that brain tumors may be stem cell 
diseases, which may lead to the development of 
new strategies to cure brain tumors. Several issues 
would need to be addressed before stem cells could 
be employed for the treatment of brain tumors. 
Among them, what are the secondary risks of using 
stem cells as vector to attack and destroy tumor 
cells? What strategies can be devised to speciﬁ  -
cally target BTSCs?
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